These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26384287)

  • 21. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
    Hisamichi H; Naito R; Toyoshima A; Kawano N; Ichikawa A; Orita A; Orita M; Hamada N; Takeuchi M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2005 Aug; 13(16):4936-51. PubMed ID: 15990316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
    Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
    Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Aug; 16(15):7347-57. PubMed ID: 18585046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
    Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
    Norman P
    Expert Opin Ther Pat; 2009 Oct; 19(10):1469-72. PubMed ID: 19552507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly potent aminopyridines as Syk kinase inhibitors.
    Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
    McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
    Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
    Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
    Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syk inhibitors with high potency in presence of blood.
    Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
    Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
    El-Ansary AK; Kamal AM; Al-Ghorafi MA
    Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.